^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

MYC translocation

i
Other names: MYC, bHLHe39, c-Myc, MYCC, V-myc avian myelocytomatosis viral oncogene homolog
Entrez ID:
Phase 3
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
04/11/2024
Initiation :
10/12/2016
Primary completion :
05/10/2024
Completion :
05/10/2024
MYC • BCL2 • BCL6 • TNFA • CARD11 • TNFAIP3 • CD79A • GSTT1
|
BCL2 expression • MYC expression • MYC translocation • CD79A mutation • CD79A mutation + CD79B mutation
|
Imbruvica (ibrutinib) • cytarabine • cyclophosphamide • etoposide IV • carmustine • melphalan • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous
Phase 2/3
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
04/04/2024
Initiation :
10/22/2019
Primary completion :
04/01/2028
Completion :
04/01/2028
MYC • BCL2 • BCL6
|
BCL2 expression • MYC expression • MYC translocation • MYC negative • BCL2 translocation
|
Venclexta (venetoclax) • Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • cyclophosphamide intravenous
Phase 3
Children's Oncology Group
Completed
Last update posted :
03/26/2024
Initiation :
03/01/2007
Primary completion :
03/01/2016
MYC
|
MYC translocation
|
cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • mercaptopurine • Kidrolase (L-asparaginase) • Neupogen (filgrastim) • cyclophosphamide intravenous
Phase 3
Mats Heyman
Recruiting
Last update posted :
03/19/2024
Initiation :
07/13/2020
Primary completion :
06/30/2027
Completion :
06/30/2032
MYC • BCL2 • KMT2A
|
MYC rearrangement + BCL2 rearrangement • MLL rearrangement • MYC rearrangement • MYC translocation • BCL2 rearrangement
|
imatinib • doxorubicin hydrochloride • Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin) • vincristine • thioguanine
Phase N/A
Swiss Group for Clinical Cancer Research
Recruiting
Last update posted :
03/15/2024
Initiation :
03/12/2024
Primary completion :
12/01/2026
Completion :
12/01/2026
TP53 • MYC • BCL2 • BCL6
|
TP53 mutation • MYC translocation • BCL2 translocation
Phase 1
BeiGene
Recruiting
Last update posted :
03/15/2024
Initiation :
06/20/2023
Primary completion :
03/01/2026
Completion :
10/01/2026
BCL2
|
MYC translocation
|
BGB-21447
Phase 2
Jennifer Crombie, MD
Recruiting
Last update posted :
02/23/2024
Initiation :
04/06/2023
Primary completion :
09/15/2026
Completion :
09/15/2029
ALK • BCL2 • CD20 • BCL6
|
ALK positive • CD20 positive • MYC translocation
|
Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • prednisone • Polivy (polatuzumab vedotin-piiq) • Columvi (glofitamab-gxbm)
Phase 2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
02/15/2024
Initiation :
08/27/2013
Primary completion :
03/26/2020
Completion :
12/31/2024
ALK • MYC • CD20 • CD4
|
CD20 expression • MYC translocation
|
Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • cyclophosphamide intravenous
Phase 1/2
Kronos Bio
Recruiting
Last update posted :
02/02/2024
Initiation :
02/08/2021
Primary completion :
12/01/2025
Completion :
12/01/2025
MYC
|
MYC translocation • KIT translocation
|
KB-0742
Phase 1
Lapo Alinari
Recruiting
Last update posted :
12/29/2023
Initiation :
03/06/2023
Primary completion :
03/05/2027
Completion :
03/05/2027
MYC • BCL2 • BCL6
|
BCL2 expression • MYC expression • MYC translocation • MYC translocation + BCL2 translocation • BCL2 translocation
|
tegavivint (BC2059)
Phase 3
University College, London
Active, not recruiting
Last update posted :
11/29/2023
Initiation :
12/01/2010
Primary completion :
12/01/2023
Completion :
07/01/2024
ABL1 • BCR • MYC
|
MYC translocation • Chr t(4;11)(q21;q23)
|
Rituxan (rituximab) • imatinib • cytarabine • cyclophosphamide • etoposide IV • vincristine • daunorubicin • melphalan • Oncaspar liquid (pegaspargase) • fludarabine IV • nelarabine • mercaptopurine • Kepivance (palifermin)
Phase 1/2
Dana-Farber Cancer Institute
Active, not recruiting
Last update posted :
10/11/2023
Initiation :
09/08/2021
Primary completion :
09/01/2024
Completion :
09/01/2025
BCL2 • BCL6
|
MYC translocation
|
Venclexta (venetoclax) • Aliqopa (copanlisib)
Phase 2
National Heart, Lung, and Blood Institute (NHLBI)
Completed
Last update posted :
09/21/2023
Initiation :
04/15/1999
Primary completion :
12/14/2018
Completion :
06/18/2020
MYC • BCL2 • CD34
|
MYC translocation
|
cyclophosphamide • fludarabine IV • cyclosporine
Phase 1/2
Cyteir Therapeutics, Inc.
Active, not recruiting
Last update posted :
07/17/2023
Initiation :
10/09/2019
Primary completion :
07/30/2024
Completion :
12/30/2024
ER • PGR • MYC • BCL2
|
HER-2 positive • HER-2 negative • ER negative • ER positive + PGR positive • PGR positive • MYC translocation • PGR negative
|
gemcitabine • Rituxan (rituximab) • capecitabine • bendamustine • CYT-0851
Phase 1
Fox Chase Cancer Center
Active, not recruiting
Last update posted :
06/22/2023
Initiation :
05/15/2018
Primary completion :
05/15/2024
Completion :
12/15/2024
MYC
|
MYC translocation
|
Opdivo (nivolumab)
Phase 1
Weill Medical College of Cornell University
Completed
Last update posted :
08/24/2022
Initiation :
02/06/2017
Primary completion :
11/11/2021
Completion :
11/11/2021
BCL2 • BCL6
|
MYC translocation
|
Venclexta (venetoclax) • Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • cyclophosphamide intravenous
Phase 2
Fudan University
Recruiting
Last update posted :
03/22/2022
Initiation :
01/04/2022
Primary completion :
01/04/2024
Completion :
01/04/2026
TP53 • MYC • MYD88 • CD79B
|
TP53 mutation • NOTCH1 mutation • MYD88 mutation • CD79B mutation • CD79B mutation • MYC translocation
|
Rituxan (rituximab) • Brukinsa (zanubrutinib)
Phase 1
Curis, Inc.
Completed
Last update posted :
05/06/2021
Initiation :
12/01/2012
Primary completion :
10/09/2020
Completion :
10/09/2020
MYC • BCL2 • BCL6 • CREBBP
|
MYC overexpression • BCL6 rearrangement • MYC translocation • BCL2 rearrangement • BCL6 translocation • BCL2 translocation
|
Venclexta (venetoclax) • Rituxan (rituximab) • fimepinostat (CUDC-907)
Phase 2
University of California, San Francisco
Withdrawn
Last update posted :
10/10/2019
Initiation :
06/13/2016
Primary completion :
04/09/2018
Completion :
04/09/2018
MYC • BCL2
|
MYC overexpression • MYC translocation